EO-4010 is under clinical development by Enterome Bioscience and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EO-4010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EO-4010 overview

EO-4010 is under development for the treatment of colorectal cancer, metastatic colorectal cancer (CRC). The therapeutic peptide vaccine is composed of five microbial-derived peptides mimicking epitopes from the tumor associated antigens (TAAs) BIRC5, FOXM1, UBE2C, CDC20, KIF2C. It is being developed based on OncoMimics platform. It is administered through subcutaneous route.

Enterome Bioscience overview

Enterome Bioscience (Enterome) is a clinical-stage biopharmaceutical company that develops immunomodulatory drugs for the treatment of cancer and immune diseases. The company’s pipeline products include memory T cell therapy and bioactives. Its pipeline candidates treat EO2401 +nivolumab, recurrent glioblastoma; EO2463, B-cell malignancies; EO2040, CRC ctDNA MRD; EO4010, CRC; EB1010, IBD and food allergy; EA300, food allergy. Its brands include OncoMimics, EndoMimics and AllerMimics. Enterome is headquartered in Paris, Ile-de-France, France.

For a complete picture of EO-4010’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.